How Epstein-Barr virus may help trigger multiple sclerosis

Could a virus that infects most adults help explain why a much smaller group develops multiple sclerosis? A new Science Translational Medicine paper by Kjetil Bjornevik and colleagues (2026) suggests the answer may be closer to yes than no. Epstein-Barr virus does not merely appear alongside MS; in this study, the immune system in MS seems to react strongly to a specific, active phase of the virus.

The paper stops well short of saying Epstein-Barr virus alone causes multiple sclerosis. It also does not show that an antiviral would prevent or reverse disease tomorrow. What it offers instead is a more concrete mechanism. In people with MS, CD4-positive T cells were especially reactive to late lytic EBV antigens, the proteins the virus expresses when it is actively making new viral particles. After anti-CD20 treatment, that immune response fell and saliva viral load dropped with it.

That is the part worth slowing down for. The field has had a strong association for years, especially after Bjornevik et al. (2022) in Science reported a 32-fold rise in MS risk after Epstein-Barr virus infection in a cohort of more than 10 million US service members. But association, even a dramatic one, still leaves room for the old question: what is the virus actually doing inside the disease process? This new paper does not close the case. It narrows the mystery.

What the new study actually found

The practical claim in Bjornevik et al. 2026 is that the immune system in multiple sclerosis is not just seeing the virus and shrugging. It is responding to the part of EBV biology tied to active replication. The study found that untreated MS was associated with roughly a twofold enrichment in EBV-specific CD4-positive T-cell responses compared with healthy controls, with the strongest signal aimed at late lytic capsid and glycoprotein antigens rather than the virus’s latent phase. That distinction matters because latent infection is common. Active viral replication is a different claim.

After treatment came the second striking result. In 60 people with MS measured before and after anti-CD20 therapy, the virus-reactive CD4 response fell by about 2.5-fold, according to the study and Nature’s coverage of the paper. Saliva EBV load also dropped. Those findings support a model in which B cells act as a reservoir for the virus, and depleting those cells reduces the viral activity that may be feeding the immune response.

Until now, the safest version of the EBV hypothesis was that the virus was a prerequisite, or at least a major risk marker, for MS. After this paper, the stronger version becomes harder to dismiss: active EBV biology may be part of the inflammatory engine itself. In an interview with STAT, Bjornevik put the shift plainly.

“It’s very nice now to be able to understand more about the underlying mechanisms of how EBV likely causes MS”

Kjetil Bjornevik, via STAT

Still, an important scientific restraint stays in place. The paper shows immune behavior consistent with causation; it does not yet prove that shutting down EBV will stop the disease course in patients who already have established MS. Mechanistic clarification is not the same thing as a clinical endpoint. Vitalspell readers should keep those two categories separate.

Why this strengthens causation but does not finish the case

This paper lands because it slots into a sequence rather than standing alone. First came the epidemiology. In Bjornevik et al. 2022 in Science, EBV infection preceded the sharp jump in MS risk, while other viral infections did not show the same pattern. Then came finer-grained immunology, including Wang et al. 2026 in Cell, which argued that EBV infection and HLA-DR15 could converge on the presentation of myelin-related peptides. Now the new paper adds evidence that the most relevant immune reaction may be tied to lytic viral antigens and to B-cell reservoirs that current therapies can disrupt.

Taken together, the layered picture looks more like causation than coincidence. One paper can show risk. Another can sketch a genetic and antigen-presentation route. A third can show what seems to happen when the relevant immune cells and viral reservoirs are pushed down. The field is no longer asking only whether Epstein-Barr virus is associated with MS. It is asking where in the chain of immune misfiring the virus sits.

Careful researchers still hedge. Around 90 percent of adults carry EBV, while only a small fraction develop MS. The virus cannot be the whole story. Host genetics, especially HLA variation, timing of infection, sex differences, environmental factors and prior immune history still matter. A plausible mechanism can coexist with incomplete prediction. That is normal in autoimmune disease research, not a contradiction.

Emily Edwards, an immunologist quoted by Nature, made the clinical implication sound promising without overstating it.

“That shows the importance of both of these groups of immune cells in driving disease, and how we can moderate that with immunotherapies to potentially reduce disease severity”

Emily Edwards, via Nature

One word to sit with there is potentially. This study helps explain why anti-CD20 therapy might work so well in some patients. It does not show that those drugs work only through EBV, and it does not prove that an antiviral aimed at EBV would outperform the immune therapies already in use. Mechanism sharpens strategy. It does not automatically deliver a finished treatment.

What it means for antivirals, vaccines and current care

The downstream consequence is narrower than a headline might suggest. If active viral replication and B-cell reservoirs are part of the disease machinery, then the case for targeting EBV directly gets stronger. That is why New Scientist’s analysis immediately turned to antivirals and vaccines. Not because this paper shows they work, but because it makes the idea less speculative.

On paper, the logic is appealing. A vaccine that prevents EBV infection, or a therapy that meaningfully suppresses the virus before the immune cascade is established, could in theory trim future MS risk or reduce one driver of ongoing disease. Yet theory is doing a lot of work in that sentence. Vaccine development remains ongoing. Antiviral trials would need to show not just biological activity against EBV, but clinically meaningful effects on relapses, disability progression or imaging markers in MS.

Clinically, this is also where outside enthusiasm needs boundaries. In the same STAT interview, neurologist Syed Rizvi argued that mechanistic steps like this matter because drug development often advances molecule by molecule.

Rizvi is right about the value of granularity. He is speaking from the optimistic edge of translational medicine, where better target maps can make entire treatment categories thinkable. Readers should hear both halves. A sharper target is progress. It is not a green light for patients to expect EBV drugs in routine MS care anytime soon.

For patients and families, that distinction is more than editorial caution. A mechanism paper can change how researchers design trials long before it changes what happens in a neurology clinic. The useful reaction is not to chase improvised antiviral regimens, but to watch whether EBV-targeted vaccines or drugs can clear the much harder tests: fewer relapses, slower disability progression, or quieter MRI activity.

For now, the cleanest way to read the paper is as a mechanism paper with genuine clinical implications. It strengthens the idea that Epstein-Barr virus is not just along for the ride in multiple sclerosis. It may be one of the processes that helps drive the ride. That is a major shift in how securely the EBV hypothesis can be discussed. It is not the final word on prevention, and it is not a cue for supplement-style immune hacks. It is a case for better trials.

Less dramatic, and more useful, is the bottom line. Bjornevik et al. 2026 make the EBV-MS link look biologically specific. Bjornevik et al. 2022 made it look epidemiologically unavoidable. Wang et al. 2026 helped explain why some immune systems may be especially vulnerable to the interaction. If future work shows that blocking EBV changes MS outcomes, this paper will look like one of the studies that made that trial strategy intellectually hard to ignore.

References

1. Bjornevik K, Mahler JV, Bilodeau PA, Rød BE, Romanow G, et al. CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis. Science Translational Medicine. 2026. https://doi.org/10.1126/scitranslmed.adz6566
2. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022. https://doi.org/10.1126/science.abj8222
3. Wang J, Qiu Y, Marti Z, Li F, Wacker M, et al. EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. Cell. 2026. https://doi.org/10.1016/j.cell.2025.12.046